Agilent Technologies (NYSE:A) was the recipient of unusually large options trading on Tuesday. Stock traders bought 5,740 put options on the stock. This is an increase of 947% compared to the average volume of 548 put options.
A number of brokerages have recently weighed in on A. Goldman Sachs upgraded Agilent Technologies from a “neutral” rating to a “buy” rating in a report on Monday, April 9th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 price target for the company in a report on Tuesday, March 27th. Morgan Stanley lowered their price target on Agilent Technologies from $95.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, April 11th. Robert W. Baird reiterated a “buy” rating and issued a $76.00 price target on shares of Agilent Technologies in a report on Thursday, January 18th. Finally, ValuEngine downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $72.20.
In other Agilent Technologies news, insider Patrick Kaltenbach sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $67.28, for a total value of $269,120.00. Following the transaction, the insider now directly owns 72,547 shares of the company’s stock, valued at approximately $4,880,962.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Heidi Fields sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 27th. The shares were sold at an average price of $68.09, for a total value of $340,450.00. Following the completion of the transaction, the director now directly owns 57,563 shares in the company, valued at $3,919,464.67. The disclosure for this sale can be found here. Insiders have sold a total of 22,700 shares of company stock worth $1,586,452 over the last three months.
A number of institutional investors and hedge funds have recently modified their holdings of A. BlackRock Inc. grew its stake in Agilent Technologies by 10.8% during the 1st quarter. BlackRock Inc. now owns 28,445,160 shares of the medical research company’s stock worth $1,902,983,000 after buying an additional 2,779,802 shares during the last quarter. OppenheimerFunds Inc. grew its stake in Agilent Technologies by 73.5% during the 1st quarter. OppenheimerFunds Inc. now owns 4,656,405 shares of the medical research company’s stock worth $311,514,000 after buying an additional 1,973,089 shares during the last quarter. Renaissance Technologies LLC grew its stake in Agilent Technologies by 325.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock worth $158,732,000 after buying an additional 1,812,500 shares during the last quarter. Old Mutual Global Investors UK Ltd. bought a new position in Agilent Technologies during the 1st quarter worth $100,067,000. Finally, Arrowstreet Capital Limited Partnership grew its stake in Agilent Technologies by 145.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock worth $115,652,000 after buying an additional 1,023,099 shares during the last quarter.
Shares of Agilent Technologies opened at $62.50 on Wednesday, according to Marketbeat. The firm has a market cap of $22.32 billion, a P/E ratio of 26.93, a P/E/G ratio of 2.38 and a beta of 1.32. The company has a quick ratio of 2.78, a current ratio of 3.23 and a debt-to-equity ratio of 0.40. Agilent Technologies has a 12 month low of $60.82 and a 12 month high of $65.16.
Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, May 14th. The medical research company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.01. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.21 billion. Agilent Technologies had a return on equity of 17.97% and a net margin of 5.02%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.58 EPS. equities analysts forecast that Agilent Technologies will post 2.71 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 25th. Investors of record on Tuesday, April 3rd were paid a dividend of $0.149 per share. The ex-dividend date of this dividend was Monday, April 2nd. This represents a $0.60 dividend on an annualized basis and a yield of 0.95%. Agilent Technologies’s payout ratio is currently 25.42%.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.